 - Prior to study entry, patients must have recovered from toxicities of prior chemotherapy and radiotherapy; for patients refractory to induction chemotherapy patient subgroup outlined above, marrow documentation of residual leukemia post chemotherapy and qualification for remaining eligibility criteria are needed prior to study entry this does not require 30 marrow blasts to be evident but a minimum of 10 blasts must be present in the marrow 